SBEV vs RNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 23, 2026

SBEV

36.1
AI Score
VS
RNA Wins

RNA

59.0
AI Score

Investment Advisor Scores

SBEV

36score
Recommendation
EXTENDED

RNA

59score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric SBEV RNA Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -93.8% -21.9% RNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 36.1/100 59.0/100 RNA
Profit Margin 0.0% -184.1% SBEV
Beta 1.00 1.00 Tie
AI Recommendation EXTENDED HOLD Tie

Relative Price Performance (Last 90 Days)

SBEV 1M: +358.2% · 3M: +92.5% RNA 1M: -40.1% · 3M: -37.1%

Current Technical Phase

SBEV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (37.2% over 20 days), RSI 67

RSI (14): 66.6 · Price: $0.47

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.4%), weak momentum, RSI 25

RSI (14): 24.8 · Price: $8.29

Fundamentals Snapshot

Metric SBEV RNA
Market Cap — —
Forward P/E 0.0 -1.0
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.9% -0.2%
Gross Margin -56.0% -0.6%
Operating Margin -238.9% -7.5%
EPS -42.54 -5.36
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.